nodes	percent_of_prediction	percent_of_DWPC	metapath
Moclobemide—CYP1A2—Riluzole—amyotrophic lateral sclerosis	0.682	1	CbGbCtD
Moclobemide—Rectal tenesmus—Riluzole—amyotrophic lateral sclerosis	0.0216	0.0793	CcSEcCtD
Moclobemide—Proctalgia—Riluzole—amyotrophic lateral sclerosis	0.0172	0.063	CcSEcCtD
Moclobemide—Anorectal discomfort—Riluzole—amyotrophic lateral sclerosis	0.0147	0.054	CcSEcCtD
Moclobemide—Delusion—Riluzole—amyotrophic lateral sclerosis	0.0114	0.0417	CcSEcCtD
Moclobemide—Apathy—Riluzole—amyotrophic lateral sclerosis	0.0113	0.0414	CcSEcCtD
Moclobemide—Metrorrhagia—Riluzole—amyotrophic lateral sclerosis	0.0113	0.0414	CcSEcCtD
Moclobemide—Flat affect—Riluzole—amyotrophic lateral sclerosis	0.0112	0.041	CcSEcCtD
Moclobemide—Dysarthria—Riluzole—amyotrophic lateral sclerosis	0.00852	0.0312	CcSEcCtD
Moclobemide—Haloperidol—SIGMAR1—amyotrophic lateral sclerosis	0.00675	1	CrCbGaD
Moclobemide—Osteoarthritis—Riluzole—amyotrophic lateral sclerosis	0.00585	0.0214	CcSEcCtD
Moclobemide—Migraine—Riluzole—amyotrophic lateral sclerosis	0.00576	0.0211	CcSEcCtD
Moclobemide—Gastritis—Riluzole—amyotrophic lateral sclerosis	0.00518	0.019	CcSEcCtD
Moclobemide—Abdominal distension—Riluzole—amyotrophic lateral sclerosis	0.00509	0.0187	CcSEcCtD
Moclobemide—Angina pectoris—Riluzole—amyotrophic lateral sclerosis	0.00493	0.0181	CcSEcCtD
Moclobemide—Dysuria—Riluzole—amyotrophic lateral sclerosis	0.00473	0.0173	CcSEcCtD
Moclobemide—Stomatitis—Riluzole—amyotrophic lateral sclerosis	0.0044	0.0161	CcSEcCtD
Moclobemide—Sweating—Riluzole—amyotrophic lateral sclerosis	0.00432	0.0158	CcSEcCtD
Moclobemide—Bradycardia—Riluzole—amyotrophic lateral sclerosis	0.00412	0.0151	CcSEcCtD
Moclobemide—Hallucination—Riluzole—amyotrophic lateral sclerosis	0.00403	0.0148	CcSEcCtD
Moclobemide—MAOB—nerve—amyotrophic lateral sclerosis	0.00355	0.118	CbGeAlD
Moclobemide—Flatulence—Riluzole—amyotrophic lateral sclerosis	0.00347	0.0127	CcSEcCtD
Moclobemide—Tension—Riluzole—amyotrophic lateral sclerosis	0.00346	0.0127	CcSEcCtD
Moclobemide—Dysgeusia—Riluzole—amyotrophic lateral sclerosis	0.00345	0.0126	CcSEcCtD
Moclobemide—Nervousness—Riluzole—amyotrophic lateral sclerosis	0.00342	0.0125	CcSEcCtD
Moclobemide—Tremor—Riluzole—amyotrophic lateral sclerosis	0.0033	0.0121	CcSEcCtD
Moclobemide—Ill-defined disorder—Riluzole—amyotrophic lateral sclerosis	0.00327	0.012	CcSEcCtD
Moclobemide—Agitation—Riluzole—amyotrophic lateral sclerosis	0.00324	0.0119	CcSEcCtD
Moclobemide—Malaise—Riluzole—amyotrophic lateral sclerosis	0.00318	0.0116	CcSEcCtD
Moclobemide—Syncope—Riluzole—amyotrophic lateral sclerosis	0.00316	0.0116	CcSEcCtD
Moclobemide—Palpitations—Riluzole—amyotrophic lateral sclerosis	0.00311	0.0114	CcSEcCtD
Moclobemide—Loss of consciousness—Riluzole—amyotrophic lateral sclerosis	0.0031	0.0114	CcSEcCtD
Moclobemide—Hypertension—Riluzole—amyotrophic lateral sclerosis	0.00304	0.0112	CcSEcCtD
Moclobemide—MAOA—nerve—amyotrophic lateral sclerosis	0.00303	0.1	CbGeAlD
Moclobemide—Chest pain—Riluzole—amyotrophic lateral sclerosis	0.003	0.011	CcSEcCtD
Moclobemide—Myalgia—Riluzole—amyotrophic lateral sclerosis	0.003	0.011	CcSEcCtD
Moclobemide—Anxiety—Riluzole—amyotrophic lateral sclerosis	0.00299	0.011	CcSEcCtD
Moclobemide—Discomfort—Riluzole—amyotrophic lateral sclerosis	0.00296	0.0109	CcSEcCtD
Moclobemide—Dry mouth—Riluzole—amyotrophic lateral sclerosis	0.00293	0.0108	CcSEcCtD
Moclobemide—Confusional state—Riluzole—amyotrophic lateral sclerosis	0.0029	0.0106	CcSEcCtD
Moclobemide—Shock—Riluzole—amyotrophic lateral sclerosis	0.00283	0.0104	CcSEcCtD
Moclobemide—Tachycardia—Riluzole—amyotrophic lateral sclerosis	0.00281	0.0103	CcSEcCtD
Moclobemide—Hyperhidrosis—Riluzole—amyotrophic lateral sclerosis	0.00278	0.0102	CcSEcCtD
Moclobemide—Hypotension—Riluzole—amyotrophic lateral sclerosis	0.00269	0.00985	CcSEcCtD
Moclobemide—MAOB—hindbrain—amyotrophic lateral sclerosis	0.00266	0.0882	CbGeAlD
Moclobemide—Musculoskeletal discomfort—Riluzole—amyotrophic lateral sclerosis	0.00262	0.0096	CcSEcCtD
Moclobemide—Insomnia—Riluzole—amyotrophic lateral sclerosis	0.0026	0.00953	CcSEcCtD
Moclobemide—Paraesthesia—Riluzole—amyotrophic lateral sclerosis	0.00258	0.00946	CcSEcCtD
Moclobemide—Dyspnoea—Riluzole—amyotrophic lateral sclerosis	0.00256	0.0094	CcSEcCtD
Moclobemide—Somnolence—Riluzole—amyotrophic lateral sclerosis	0.00256	0.00937	CcSEcCtD
Moclobemide—Dyspepsia—Riluzole—amyotrophic lateral sclerosis	0.00253	0.00928	CcSEcCtD
Moclobemide—Decreased appetite—Riluzole—amyotrophic lateral sclerosis	0.0025	0.00916	CcSEcCtD
Moclobemide—Fatigue—Riluzole—amyotrophic lateral sclerosis	0.00248	0.00909	CcSEcCtD
Moclobemide—Constipation—Riluzole—amyotrophic lateral sclerosis	0.00246	0.00901	CcSEcCtD
Moclobemide—Feeling abnormal—Riluzole—amyotrophic lateral sclerosis	0.00237	0.00869	CcSEcCtD
Moclobemide—Gastrointestinal pain—Riluzole—amyotrophic lateral sclerosis	0.00235	0.00862	CcSEcCtD
Moclobemide—Urticaria—Riluzole—amyotrophic lateral sclerosis	0.00229	0.00837	CcSEcCtD
Moclobemide—Abdominal pain—Riluzole—amyotrophic lateral sclerosis	0.00227	0.00833	CcSEcCtD
Moclobemide—MAOA—hindbrain—amyotrophic lateral sclerosis	0.00227	0.0752	CbGeAlD
Moclobemide—Asthenia—Riluzole—amyotrophic lateral sclerosis	0.00206	0.00756	CcSEcCtD
Moclobemide—Pruritus—Riluzole—amyotrophic lateral sclerosis	0.00204	0.00746	CcSEcCtD
Moclobemide—Diarrhoea—Riluzole—amyotrophic lateral sclerosis	0.00197	0.00721	CcSEcCtD
Moclobemide—Dizziness—Riluzole—amyotrophic lateral sclerosis	0.0019	0.00697	CcSEcCtD
Moclobemide—Vomiting—Riluzole—amyotrophic lateral sclerosis	0.00183	0.0067	CcSEcCtD
Moclobemide—Rash—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00665	CcSEcCtD
Moclobemide—Dermatitis—Riluzole—amyotrophic lateral sclerosis	0.00181	0.00664	CcSEcCtD
Moclobemide—Headache—Riluzole—amyotrophic lateral sclerosis	0.0018	0.0066	CcSEcCtD
Moclobemide—Nausea—Riluzole—amyotrophic lateral sclerosis	0.00171	0.00626	CcSEcCtD
Moclobemide—MAOB—embryo—amyotrophic lateral sclerosis	0.00166	0.0551	CbGeAlD
Moclobemide—MAOB—brainstem—amyotrophic lateral sclerosis	0.00152	0.0505	CbGeAlD
Moclobemide—MAOA—embryo—amyotrophic lateral sclerosis	0.00142	0.047	CbGeAlD
Moclobemide—CYP2D6—hindbrain—amyotrophic lateral sclerosis	0.00135	0.0447	CbGeAlD
Moclobemide—MAOA—brainstem—amyotrophic lateral sclerosis	0.0013	0.0431	CbGeAlD
Moclobemide—MAOB—medulla oblongata—amyotrophic lateral sclerosis	0.00106	0.0352	CbGeAlD
Moclobemide—MAOB—spinal cord—amyotrophic lateral sclerosis	0.000948	0.0314	CbGeAlD
Moclobemide—MAOA—medulla oblongata—amyotrophic lateral sclerosis	0.000907	0.0301	CbGeAlD
Moclobemide—MAOA—spinal cord—amyotrophic lateral sclerosis	0.000809	0.0268	CbGeAlD
Moclobemide—MAOB—nervous system—amyotrophic lateral sclerosis	0.000799	0.0265	CbGeAlD
Moclobemide—CYP2D6—brainstem—amyotrophic lateral sclerosis	0.000773	0.0256	CbGeAlD
Moclobemide—MAOB—central nervous system—amyotrophic lateral sclerosis	0.000769	0.0255	CbGeAlD
Moclobemide—MAOB—cerebellum—amyotrophic lateral sclerosis	0.000752	0.0249	CbGeAlD
Moclobemide—MAOA—nervous system—amyotrophic lateral sclerosis	0.000682	0.0226	CbGeAlD
Moclobemide—MAOA—central nervous system—amyotrophic lateral sclerosis	0.000656	0.0217	CbGeAlD
Moclobemide—MAOA—cerebellum—amyotrophic lateral sclerosis	0.000641	0.0213	CbGeAlD
Moclobemide—MAOB—brain—amyotrophic lateral sclerosis	0.000611	0.0202	CbGeAlD
Moclobemide—MAOA—Biogenic Amine Synthesis—CHAT—amyotrophic lateral sclerosis	0.000556	0.0687	CbGpPWpGaD
Moclobemide—MAOB—Dopamine metabolism—SOD1—amyotrophic lateral sclerosis	0.000547	0.0676	CbGpPWpGaD
Moclobemide—MAOA—brain—amyotrophic lateral sclerosis	0.000521	0.0173	CbGeAlD
Moclobemide—MAOA—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000509	0.0629	CbGpPWpGaD
Moclobemide—CYP2D6—nervous system—amyotrophic lateral sclerosis	0.000405	0.0134	CbGeAlD
Moclobemide—CYP2D6—central nervous system—amyotrophic lateral sclerosis	0.00039	0.0129	CbGeAlD
Moclobemide—MAOA—Oxidative Stress—GSR—amyotrophic lateral sclerosis	0.000389	0.048	CbGpPWpGaD
Moclobemide—CYP2D6—cerebellum—amyotrophic lateral sclerosis	0.000381	0.0126	CbGeAlD
Moclobemide—MAOA—Dopamine metabolism—SOD1—amyotrophic lateral sclerosis	0.000343	0.0424	CbGpPWpGaD
Moclobemide—CYP2D6—brain—amyotrophic lateral sclerosis	0.00031	0.0103	CbGeAlD
Moclobemide—MAOA—Neurotransmitter Release Cycle—CHAT—amyotrophic lateral sclerosis	0.000244	0.0301	CbGpPWpGaD
Moclobemide—CYP2C19—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000241	0.0298	CbGpPWpGaD
Moclobemide—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—amyotrophic lateral sclerosis	0.000237	0.0293	CbGpPWpGaD
Moclobemide—CYP2D6—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000221	0.0274	CbGpPWpGaD
Moclobemide—MAOA—Neurotransmitter Release Cycle—SLC6A1—amyotrophic lateral sclerosis	0.000217	0.0269	CbGpPWpGaD
Moclobemide—CYP1A2—Melatonin metabolism and effects—ECE1—amyotrophic lateral sclerosis	0.000188	0.0232	CbGpPWpGaD
Moclobemide—MAOA—Oxidative Stress—SOD1—amyotrophic lateral sclerosis	0.000176	0.0217	CbGpPWpGaD
Moclobemide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000158	0.0195	CbGpPWpGaD
Moclobemide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—RARA—amyotrophic lateral sclerosis	0.000135	0.0167	CbGpPWpGaD
Moclobemide—MAOA—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	0.000133	0.0165	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—ECE1—amyotrophic lateral sclerosis	0.000132	0.0164	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—KCNJ10—amyotrophic lateral sclerosis	9.23e-05	0.0114	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—SLC1A3—amyotrophic lateral sclerosis	8.53e-05	0.0106	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—AQP4—amyotrophic lateral sclerosis	8.53e-05	0.0106	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—CHAT—amyotrophic lateral sclerosis	8.53e-05	0.0106	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—GRIA2—amyotrophic lateral sclerosis	8.52e-05	0.0105	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—SLC1A2—amyotrophic lateral sclerosis	8.23e-05	0.0102	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—NEFL—amyotrophic lateral sclerosis	7.52e-05	0.0093	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—KCNJ10—amyotrophic lateral sclerosis	7.07e-05	0.00874	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—SLC1A3—amyotrophic lateral sclerosis	6.99e-05	0.00865	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—CHAT—amyotrophic lateral sclerosis	6.99e-05	0.00865	CbGpPWpGaD
Moclobemide—MAOB—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	6.76e-05	0.00836	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—GRIA2—amyotrophic lateral sclerosis	6.53e-05	0.00807	CbGpPWpGaD
Moclobemide—CYP2C19—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	6.31e-05	0.0078	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—SLC1A2—amyotrophic lateral sclerosis	6.3e-05	0.00779	CbGpPWpGaD
Moclobemide—MAOA—Transmission across Chemical Synapses—SLC6A1—amyotrophic lateral sclerosis	6.23e-05	0.00771	CbGpPWpGaD
Moclobemide—CYP2D6—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	5.8e-05	0.00717	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—NEFL—amyotrophic lateral sclerosis	5.76e-05	0.00713	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—SLC1A3—amyotrophic lateral sclerosis	5.36e-05	0.00663	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—CHAT—amyotrophic lateral sclerosis	5.36e-05	0.00663	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—VAPB—amyotrophic lateral sclerosis	5.18e-05	0.0064	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—TPK1—amyotrophic lateral sclerosis	5.18e-05	0.0064	CbGpPWpGaD
Moclobemide—CYP2C19—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.96e-05	0.00613	CbGpPWpGaD
Moclobemide—CYP1A2—Melatonin metabolism and effects—APOE—amyotrophic lateral sclerosis	4.91e-05	0.00608	CbGpPWpGaD
Moclobemide—MAOA—Neuronal System—SLC6A1—amyotrophic lateral sclerosis	4.78e-05	0.00591	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—VAPA—amyotrophic lateral sclerosis	4.74e-05	0.00586	CbGpPWpGaD
Moclobemide—CYP2C9—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	4.52e-05	0.00559	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	4.49e-05	0.00555	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—BDNF—amyotrophic lateral sclerosis	4.41e-05	0.00546	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—SACM1L—amyotrophic lateral sclerosis	4.4e-05	0.00545	CbGpPWpGaD
Moclobemide—MAOA—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	4.24e-05	0.00524	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—FIG4—amyotrophic lateral sclerosis	4.14e-05	0.00512	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	4.13e-05	0.0051	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	4.09e-05	0.00506	CbGpPWpGaD
Moclobemide—CYP1A2—Arachidonic acid metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.86e-05	0.00478	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—DAO—amyotrophic lateral sclerosis	3.74e-05	0.00463	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—GSR—amyotrophic lateral sclerosis	3.5e-05	0.00432	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	3.45e-05	0.00427	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—TPK1—amyotrophic lateral sclerosis	3.25e-05	0.00402	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—VAPB—amyotrophic lateral sclerosis	3.25e-05	0.00402	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	3.16e-05	0.00391	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	3.15e-05	0.00389	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—VAPA—amyotrophic lateral sclerosis	2.97e-05	0.00368	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	2.94e-05	0.00363	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	2.88e-05	0.00356	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PLB1—amyotrophic lateral sclerosis	2.84e-05	0.00351	CbGpPWpGaD
Moclobemide—CYP2C19—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	2.79e-05	0.00346	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—SACM1L—amyotrophic lateral sclerosis	2.76e-05	0.00342	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	2.76e-05	0.00341	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—VAPB—amyotrophic lateral sclerosis	2.69e-05	0.00333	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	2.68e-05	0.00331	CbGpPWpGaD
Moclobemide—CYP1A2—Phase II conjugation—GSTP1—amyotrophic lateral sclerosis	2.67e-05	0.00331	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GSR—amyotrophic lateral sclerosis	2.62e-05	0.00324	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—FIG4—amyotrophic lateral sclerosis	2.6e-05	0.00321	CbGpPWpGaD
Moclobemide—CYP2C9—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	2.55e-05	0.00315	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	2.52e-05	0.00311	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—VAPA—amyotrophic lateral sclerosis	2.46e-05	0.00304	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—DAO—amyotrophic lateral sclerosis	2.35e-05	0.00291	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—amyotrophic lateral sclerosis	2.33e-05	0.00288	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—SACM1L—amyotrophic lateral sclerosis	2.29e-05	0.00283	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—CASP3—amyotrophic lateral sclerosis	2.21e-05	0.00273	CbGpPWpGaD
Moclobemide—CYP1A2—Arachidonic acid metabolism—PTGS2—amyotrophic lateral sclerosis	2.18e-05	0.00269	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—FIG4—amyotrophic lateral sclerosis	2.15e-05	0.00266	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—CHAT—amyotrophic lateral sclerosis	2.15e-05	0.00266	CbGpPWpGaD
Moclobemide—CYP2C19—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	2.01e-05	0.00248	CbGpPWpGaD
Moclobemide—CYP2C19—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.98e-05	0.00245	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.89e-05	0.00234	CbGpPWpGaD
Moclobemide—MAOA—SIDS Susceptibility Pathways—VEGFA—amyotrophic lateral sclerosis	1.87e-05	0.00231	CbGpPWpGaD
Moclobemide—CYP2D6—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.85e-05	0.00228	CbGpPWpGaD
Moclobemide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—amyotrophic lateral sclerosis	1.83e-05	0.00227	CbGpPWpGaD
Moclobemide—CYP2C9—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.83e-05	0.00226	CbGpPWpGaD
Moclobemide—CYP2D6—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.82e-05	0.00225	CbGpPWpGaD
Moclobemide—CYP2C9—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.81e-05	0.00223	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PLB1—amyotrophic lateral sclerosis	1.78e-05	0.0022	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.73e-05	0.00213	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GSR—amyotrophic lateral sclerosis	1.64e-05	0.00203	CbGpPWpGaD
Moclobemide—CYP1A2—Biological oxidations—GSTP1—amyotrophic lateral sclerosis	1.56e-05	0.00193	CbGpPWpGaD
Moclobemide—CYP1A2—Metapathway biotransformation—GSTP1—amyotrophic lateral sclerosis	1.54e-05	0.00191	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—VAPB—amyotrophic lateral sclerosis	1.54e-05	0.0019	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—TPK1—amyotrophic lateral sclerosis	1.54e-05	0.0019	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PLB1—amyotrophic lateral sclerosis	1.47e-05	0.00182	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.43e-05	0.00177	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—TPK1—amyotrophic lateral sclerosis	1.41e-05	0.00175	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—VAPB—amyotrophic lateral sclerosis	1.41e-05	0.00175	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—VAPA—amyotrophic lateral sclerosis	1.41e-05	0.00174	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—VAPB—amyotrophic lateral sclerosis	1.4e-05	0.00173	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—TPK1—amyotrophic lateral sclerosis	1.4e-05	0.00173	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—CHAT—amyotrophic lateral sclerosis	1.35e-05	0.00167	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.31e-05	0.00162	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.31e-05	0.00162	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—VAPA—amyotrophic lateral sclerosis	1.29e-05	0.0016	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—VAPA—amyotrophic lateral sclerosis	1.28e-05	0.00159	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—FIG4—amyotrophic lateral sclerosis	1.23e-05	0.00152	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.2e-05	0.00149	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—VAPB—amyotrophic lateral sclerosis	1.2e-05	0.00148	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—TPK1—amyotrophic lateral sclerosis	1.2e-05	0.00148	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.19e-05	0.00147	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—GSTP1—amyotrophic lateral sclerosis	1.16e-05	0.00143	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—FIG4—amyotrophic lateral sclerosis	1.13e-05	0.0014	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—FIG4—amyotrophic lateral sclerosis	1.12e-05	0.00139	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—CHAT—amyotrophic lateral sclerosis	1.12e-05	0.00138	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—DAO—amyotrophic lateral sclerosis	1.11e-05	0.00138	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—VAPA—amyotrophic lateral sclerosis	1.1e-05	0.00136	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	1.06e-05	0.00131	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—DAO—amyotrophic lateral sclerosis	1.02e-05	0.00126	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—SACM1L—amyotrophic lateral sclerosis	1.02e-05	0.00126	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—DAO—amyotrophic lateral sclerosis	1.01e-05	0.00125	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—FIG4—amyotrophic lateral sclerosis	9.58e-06	0.00118	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—APOE—amyotrophic lateral sclerosis	8.74e-06	0.00108	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—DAO—amyotrophic lateral sclerosis	8.67e-06	0.00107	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PLB1—amyotrophic lateral sclerosis	8.43e-06	0.00104	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GSR—amyotrophic lateral sclerosis	7.78e-06	0.000962	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PLB1—amyotrophic lateral sclerosis	7.75e-06	0.000959	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PLB1—amyotrophic lateral sclerosis	7.69e-06	0.00095	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—GSTP1—amyotrophic lateral sclerosis	7.25e-06	0.000897	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GSR—amyotrophic lateral sclerosis	7.15e-06	0.000885	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GSR—amyotrophic lateral sclerosis	7.09e-06	0.000877	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	7.08e-06	0.000876	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	6.67e-06	0.000824	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PLB1—amyotrophic lateral sclerosis	6.57e-06	0.000812	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	6.46e-06	0.000799	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—CHAT—amyotrophic lateral sclerosis	6.39e-06	0.00079	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GSR—amyotrophic lateral sclerosis	6.06e-06	0.000749	CbGpPWpGaD
Moclobemide—MAOB—Metabolism—PTGS2—amyotrophic lateral sclerosis	5.99e-06	0.00074	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—CHAT—amyotrophic lateral sclerosis	5.88e-06	0.000726	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	5.83e-06	0.000721	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—CHAT—amyotrophic lateral sclerosis	5.82e-06	0.00072	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PLA2G4A—amyotrophic lateral sclerosis	5.52e-06	0.000683	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—APOE—amyotrophic lateral sclerosis	5.48e-06	0.000678	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	5.31e-06	0.000657	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—CHAT—amyotrophic lateral sclerosis	4.98e-06	0.000615	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—amyotrophic lateral sclerosis	4.54e-06	0.000562	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.99e-06	0.000494	CbGpPWpGaD
Moclobemide—MAOA—Metabolism—PTGS2—amyotrophic lateral sclerosis	3.76e-06	0.000465	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.64e-06	0.00045	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.43e-06	0.000425	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.16e-06	0.00039	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	3.15e-06	0.00039	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—GSTP1—amyotrophic lateral sclerosis	3.13e-06	0.000387	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—amyotrophic lateral sclerosis	3.11e-06	0.000385	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.9e-06	0.000359	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.88e-06	0.000356	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—GSTP1—amyotrophic lateral sclerosis	2.68e-06	0.000331	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—APOE—amyotrophic lateral sclerosis	2.6e-06	0.000321	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PLA2G4A—amyotrophic lateral sclerosis	2.46e-06	0.000304	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—APOE—amyotrophic lateral sclerosis	2.39e-06	0.000295	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—APOE—amyotrophic lateral sclerosis	2.37e-06	0.000293	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—APOE—amyotrophic lateral sclerosis	2.02e-06	0.00025	CbGpPWpGaD
Moclobemide—CYP2C19—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.78e-06	0.00022	CbGpPWpGaD
Moclobemide—CYP2D6—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.64e-06	0.000202	CbGpPWpGaD
Moclobemide—CYP2C9—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.62e-06	0.000201	CbGpPWpGaD
Moclobemide—CYP1A2—Metabolism—PTGS2—amyotrophic lateral sclerosis	1.39e-06	0.000171	CbGpPWpGaD
